NIPH Clinical Trials Search

UMIN ID: UMIN000032686

Registered date:24/05/2018

A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer(WJOG10417GTR)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedGastric Cancer
Date of first enrollment2018/07/02
Target sample size100
Countries of recruitmentJapan
Study typeObservational


Primary OutcomeTo explore the factors related of efficacy of nivolumab such as response, progression free survival and overall survival
Secondary OutcomeTo explore the mechanism of intrinsic and acquired resistance of nivolumab

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1) Synchronous or metachronous malignancies 2) A positive test result for any of the followings: Human immunodeficiency virus antibody, hepatitis B surfaces (HBs) antigen, or hepatitis C virus antibody 3) Positive test result for either HBs antibody or hepatitis B core antibody, with a detectable level of hepatitis B virus-deoxyribonucleic acid (HBV-DNA) even in case of negative HBs antigen test 4) Judged to be incapable of providing consent for certain reasons, such as concurrent dementia

Related Information


public contact
Name Shinichiro Nakamura
Address Namba Plaza Bldg. 304-1-5-7, Motomachi Naniwa-ku, Osaka 556-0016 JAPAN Japan
Telephone 06-6633-7400
Affiliation West Japan Oncology Group WJOG datacenter
scientific contact
Name Narikazu Boku
Address 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan Japan
Telephone 03-3542-2511
Affiliation National Cancer Center Hospital Gastrointestinal Medical Oncology Division